We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current ALTME market cap is 6.92M. The company's latest EPS is EUR -0.5433 and P/E is -0.46.
| Year End 31 December 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Revenue | 378k | 279k | 147k | 82k | 34k |
| Operating Income | -4.32M | -3.94M | -5.75M | -13.45M | -12M |
| Net Income | -10.73M | -861k | -10.41M | -14.45M | -15.13M |
| Year End 31 December 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Assets | 4.52M | 1.73M | 10.65M | 9.77M | 5.24M |
| Total Liabilities | 7.13M | 3.59M | 2.96M | 5.27M | 6.51M |
| Total Equity | -2.61M | -1.85M | 7.7M | 4.5M | -1.27M |
| Year End 31 December 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Operating | -4M | -4.29M | -5.22M | -12.38M | -12.14M |
| Investing | 66k | -16k | -39k | -14k | -21k |
| Financing | 7.6M | 1.4M | 14.18M | 11.5M | 7.29M |
| Market Cap | 6.92M |
| Price to Earnings Ratio | -0.46 |
| Price to Sales Ratio | 208.33 |
| Price to Cash Ratio | 1.5 |
| Price to Book Ratio | -5.47 |
| Dividend Yield | - |
| Shares Outstanding | 27.85M |
| Average Volume (1 week) | 354.66k |
| Average Volume (1 Month) | 378.12k |
| 52 Week Change | -84.74% |
| 52 Week High | 2.20 |
| 52 Week Low | 0.1902 |
| Spread (Intraday) | 0.02 (6.95%) |
| Company Name | Noxxon Pharma NV |
| Address |
max-dohrn-strasse 8-10 berlin 10589 |
| Website | https://www.tmepharma.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
